Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Key Takeaways Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.

Here are some of the biggest premarket U.S. stock movers today: Palo Alto Networks (NASDAQ: PANW) stock rose 0.4%, with the ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in ...

Amalgam Rx, a company offering tools that can be integrated into a healthcare provider's existing EHR, announced a $20 million credit investment from Catalio Capital Management. The senior secured ...

The complaint alleges the Indianapolis-based drugmaker offered illegal incentives to influence Texas providers to prescribe Lilly medications including Zepbound and Mounjaro.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...